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Abstract 
Schizophrenia is a serious mental disorder characteristic of several neurotransmitters 
including dopamine, serotonin, and glutamate being in imbalance. Early therapies focused solely 
on dopamine antagonism and second-generation antipsychotics focused on the dopamine and 
serotonin systems and their respective G protein coupled receptor (GPCR) proteins. Although 
debate for dimerization of certain classes of GPCR exist, the establishment of an mGlu2-5-HT2A 
heterocomplex, which is implicated in schizophrenia is of interest. Previous studies have used a 
mutation-based approach to identify transmembrane domain 4 (TM4) as the domain responsible 
in mGlu2 for mediating heteromerization before narrowing down the individual amino acids 
responsible for the interface. A similar approach to consider which portion of 5-HT2A is 
responsible for the heterodimeric interface was used in this study. We confirm that wild type 5-
HT2A and mGlu2 coimmunoprecipitate. Two 5-HT2A chimeric constructs involving full and 
partial N terminal half TM4 mutations were created using aligned residues of 5-HT2C (which is 
unable to dimerize with mGlu2). In addition to providing valuable insight into the structural 
arrangement of GPCR heteromers involving different families, these findings offer future 
direction for photo-crosslinking experiments aiming to identify individual amino acids within the 
5-HT2A responsible for mediating the heteromeric interface of the mGlu2-5-HT2A complex.
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Introduction 
Schizophrenia 
Schizophrenia is a debilitating and deteriorating mental disorder that affects roughly 1% 
of the world population (Saha, 2005). Schizophrenic patients report a combination of positive, 
psychotic symptoms including hallucinations and delusions in addition to several neurocognitive 
deficiencies (generally attributed as the negative and cognitive symptoms of schizophrenia.) 
These symptoms are outlined in the table below and there are key differences in the distribution 
of positive, negative, and cognitive symptoms when comparing schizophrenia patients to those of 
affective psychosis such as bipolar disorder and psychotic depression (Saha, 2007). While some 
schizophrenic subjects are more aware than others that their positive psychotic symptoms cannot 
be a manifestation of reality, the persistent hallucinations and delusions remain a relentless issue 
for the patient which can affect their ability to socially integrate in society; patients may also 
experience impaired judgment due to these positive effects; for example, a schizophrenic patient 
acting upon an auditory hallucination which he/she perceived to have heard, despite its absence 
in reality.  
Table of Positive, Negative, and Cognitive Symptoms in Schizophrenia 
Positive Effects Negative Effects Cognitive Effects 
Hallucinations  Speech Poverty (Alogia) Attention deficit 
Delusions Lack of emotion / interest 
/Asociality 
Verbal, Visual, and 
Working Memory deficit 
 Apathy or Inexpression Executive Function 
(Reasoning) deficit 
 Anhedonia Social Cognition deficit 
Table 1. List of Positive (Psychotic), Negative, and Cognitive effects of Schizophrenia 
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Although the more commonly mentioned symptoms of schizophrenia tend to be positive 
or psychotic in nature, the negative and cognitive effects of the disease can be equally 
debilitating. Negative symptoms, as implied in the name, represent an absence or reduction, for 
example, in speech (alogia). Anhedonia – an inability to feel pleasure – and blunted affect, 
characterized by reduced general expression, are also considered to be negative schizophrenic 
symptoms (Andreasen, 1982.) The cognitive symptoms of schizophrenia, as outlined by the 
MATRIX (Measurement and Treatment Research in Cognition in Schizophrenia) project, 
adversely affect “speed of processing, sustained attention, working memory, verbal learning, 
visual learning, executive function, and social cognition” (Nuechterlein, 2004). The cognitive 
changes associated with schizophrenia may present earlier than symptoms of psychosis and last 
the duration of the patient’s lifetime (Ibrahim, 2012).  
Positive symptoms can be treated with typical and atypical antipsychotics as detailed later 
in the text. Many antipsychotic drugs do not eliminate the negative or cognitive symptoms of 
schizophrenia; however, these symptoms are often the reason schizophrenics patients have 
difficulty participating in society (for example: cognitive dysfunction resulting in inability to live 
independently, ineptitude in social situations making it tough to maintain relationships; lack of 
motivation/interest leading to diminished quality of life in general (Miyamoto, 2012).  
The life span of an average schizophrenic subject is usually 15 years shorter than the 
general population, indicating additional costs associated with the disease that expand beyond 
the positive and negative symptoms described above (Saha et al., 2007). The risk of morbidity is 
further exaggerated in schizophrenic patients displaying conditions such as respiratory and 
cardiovascular disease (Olfson, 2015). As with many mental disorders the risk of suicide  is 
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increased  and studies estimate that patients experience a lifetime risk of suicide around 5-10% 
(Hor, 2010; Freedman 2003),  this risk, although still present, can be exponentially lowered with 
treatment, particularly with atypical antipsychotic clozapine, detailed later in this paper (Meltzer, 
2013). Most patients experience an onset of the disease between ages 15-35 (Kurita et al., 2016). 
Given the nature of the disease, it becomes apparent that schizophrenia is a mentally and 
physically debilitating condition with costs reaching beyond the initial symptoms displayed by 
patients. 
Dopamine in Schizophrenia and the Emergence of Typical Antipsychotics 
Schizophrenic symptoms are generally attributed to dysfunction in dopamine 
neurotransmission in the brain. Dysregulation of the dopamine circuit may present itself in 
schizophrenic patients as an overstimulated mesolimbic dopamine pathway with a concurrent 
lack of dopamine activity in the mesocortical pathway (Davis et al., 1991). The positive 
symptoms of schizophrenia are associated with the hyper stimulation of neuronal projections on 
D2 receptors in the mesolimbic pathway. On the other hand, dopamine D1 receptors experience 
hypo-stimulation due to mesocortical projections to the prefrontal cortex being less active 
(Guillin, 2007).  
These alterations produced by schizophrenia can affect the activity of pyramidal neurons 
in the prefrontal cortex, which serve roles in information processing, but also in the interneuron, 
which plays key regulatory roles in neurotransmitter release by acting on pyramidal cells.  
(Freedman, 2003.) The general function between these types of cells is shown to be disrupted by 
evidence suggesting that the density of synaptic connections between neurons and interneurons is 
 
 
4 
 
 
reduced. Activity between neurons and interneurons can be modulated by dopamine afferents but 
also by serotonergic, cholinergic, and noradrenergic cortical afferents (Freedman, 2003). 
Before exploring these other neurotransmitters systems, a discussion of the first 
generational class of antipsychotic drugs focused on the dopamine system, is necessary. 
Specifically, the first antipsychotics focused on dopamine receptor antagonism due to the 
establishment of hyperexcitation in dopamine pathways leading to positive psychotic symptoms. 
This class of antipsychotics were known as first generational antipsychotic drugs and include 
haloperidol and perphenazine. While effective in mediating antipsychotic effects through D2 
receptor blockade, this generation of antipsychotic drugs presented patients with side effects 
such as weight gain, temperature dysregulation, and most notably, extrapyramidal side effects 
(EPS) at clinically effective doses (Leucht, 2009). These EPS effects can be compared to the 
tremors and bradykinesia experienced by Parkinson’s patients and result in overall reduction of 
motor function. A distinction between typical and atypical antipsychotics can be made by the 
absence of EPS in atypical antipsychotics (discussed further below); for this reason, many first 
generation APDs are classified as typical. Although, typical APDs seemed to be somewhat 
effective in alleviating positive symptoms, the presence of EPS symptoms and consideration of 
targets other than dopamine receptors encouraged research of a second generation of 
antipsychotic drugs. 
Serotonin in Schizophrenia and the Emergence of Atypical Antipsychotics 
As mentioned above, many other neurotransmitter systems are implicated in 
schizophrenia in addition to dopamine dysregulation. Unlike first generational APDs which were 
often supplemented by anti-parkinsonian drugs to limit their extrapyramidal side effects, patients 
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using second generation APDs reported fewer EPS symptoms. Clozapine was the first such drug 
developed (Meltzer, 2012), and its therapeutic effects were achieved by a combination of 
dopamine D1 and D2 antagonism coupled with 5-HT2A antagonism.  
Clozapine and other second generational APDs developed after it are generally 
considered atypical since they do not induce the EPS motor disturbances associated with 
administration of typical first generational APDs; however, there is some variation in the exact 
classification of typical and atypical APDs (Meltzer, 2013). Other atypical drugs which inhibit 
both D2 and 5-HT2A receptors, in a manner similar to clozapine include risperidone and 
quetiapine (Tran et al., 1997; Small et al., 1997). Later atypical psychotics acting as full or 
partial agonists and antagonist in dopamine and serotonin receptors were also developed; this 
includes amisulpride (strong 5-HT7 antagonist) and cariprazine (partial 5-HT2B/5-HT1A 
antagonist/agonist). All of these drugs are characteristic of positive symptom suppression. 
In terms of efficacy, clozapine was shown to decrease positive psychotic symptoms with 
exceptional efficacy in patients displaying Treatment Resistant Schizophrenia (TRS) which 
accounts for roughly 30% of all schizophrenic patients (Meltzer, 1997); a patient is considered to 
have TRS following two or more unsuccessful treatments with other APDs. Although it is not 
clear whether atypical antipsychotics are superior to typical antipsychotics in terms of efficacy in 
non TRS patients, the presence of motor side effects (possibly resulting in the need to take 
additional drugs to limit these effects) in typical APDs may be a key factor in selecting atypical 
drugs over typical APDs. 
The focus of many early antipsychotics in regulating solely dopamine receptor activity 
before the later development of multitargeted atypical antipsychotics to provide simultaneous 
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dopaminergic and serotonergic inhibition begs a question: what other neurotransmitters or 
receptors can be considered in the characterization of schizophrenia in addition to dopamine, 
serotonin, and their respective receptors? To assess this, we begin by considering psychedelics, 
which are intimately involved with the serotonin receptor 5-HT2A. 
General GPCR characteristics and Psychedelics as a Model of Schizophrenia 
Psychedelic compounds can produce altered perception and distort feeling and include 
the compounds LSD (lysergic acid diethylamide) and psilocybin (C12H17N2O4P) (Hanks, 2016). 
LSD was first discovered by Dr. Albert Hoffman in 1943 after which the structural similarities 
between serotonin and LSD were examined more closely, and psychedelic substances were 
ultimately categorized as 5-HT2A serotonin receptor agonists. Psychedelic substances induce 
feelings like those of positive schizophrenic symptoms (Hanks, 2016). Due to this, psychedelics 
have been used in numerous animal models of schizophrenia in which psychedelic agonists, but 
not non-psychedelic 5-HT2A agonists, produce a head twitch response, a behavior analogous to 
positive hallucinogenic symptoms, in rodents (González-Maeso, 2007). The head twitch 
movements are not found in knockout mice missing the 5-HT2A receptor (González-Maeso, 
2007); thus, suggesting that the psychedelic effect of LSD and other psychedelics such as 
psilocybin is mediated by 5-HT2A agonist activity. 
The affinity of psychedelic compounds to GPCRs such as 5-HT2A is of interest as the 
serotonin receptor, particularly the 5-HT2A, is a target of atypical antipsychotics, such as 
clozapine detailed above. Since dopamine D1 and D2 receptors as well as the 5-HT2A receptor 
fall under the classification of GPCRs, the general structure and functional basis of GPCRs 
should be considered. 
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Serotonin (5-HT), Dopamine (D1/2), and metabotropic Glutamate (mGlu2/3) receptors 
(detailed below) fall under the family of GPCRs of which over 800 different types were 
identified in the human genome (Davenport, 2013). GPCRs contain 7 conserved heptahelical 
transmembrane domains connected by intracellular and extracellular loop residues; an 
extracellular N terminus and intracellular C terminus is also characterized by sites for 
extracellular ligand binding and glycosylation, and intracellular phosphorylation (Gonzalez-
Maeso, 2006). As the name suggests, GPCRs allow for intracellular signaling cascades in which 
ligand binding allows for activation of attached G protein; more specifically the alpha subunit of 
the GPCR dissociates from the beta/gamma subunits and allow the subunits to regulate 
respective effectors.  The adopted schematic below from Principles of Endocrinology and 
Hormone Action, 2018 shows the general features of a GPCR mentioned above. 
 
Schematic adopted from: Principles of Endocrinology 
and Hormone Action  
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Depending on the type of G protein, a signaling cascade involving activation of second 
messengers such as cAMP, calcium, and protein kinases can be detected (Pincas et al., 2018). 
For example, the 5-HT2A receptor is Gq/11-coupled resulting in Inositol trisphosphate and 
diacylglycerol (IP3/DAG) mediated calcium release from the endoplasmic reticulum upon 
receptor activation. The metabotropic glutamate receptor, discussed later in the paper, utilizes 
Gi/o-coupled signaling, characteristic of inhibiting adenylyl cyclase, and thus downstream cAMP 
production (Gonzalez-Maeso, 2011.) The dopamine D2 receptor is also Gi/o-coupled while the 
D1 receptor is Gs/olf-coupled and has essentially the opposite effect: activation of adenylyl 
cyclase and activation of cAMP (Gurevich, 2016). Finally, G11/12-coupled GPCRs activate the 
Rho family of GTPases and serve functions primarily in cytoskeletal remodeling and migration 
of fibroblast and endothelial cells (Dhanasekaran, 1996; Shan 2006).  
GPCRs were originally separated into 3 major classes based on structure: class A 
rhodopsin like receptors, class B secretin family receptor, and class C metabotropic glutamate 
receptors. However, adhesion class and frizzled class GPCRs can also be considered for a total 
of 5 families (Lee et al. 2015). There is no shared sequence homology among the different 
classes of GPCR; the greatest homology usually occurs in the cores of transmembrane domains 
of GPCRs within the same family. GPCRs contain orthostatic sites for endogenous ligand 
binding but also contain allosteric sites which do not bind ligand; rather they bind to Positive 
(PAMS) or Negative Allosteric Modifiers (NAMS) which can modulate response to an 
orthostatic agent (ligand) binding - the existence of several potential targets present in GPCRs 
may explain why almost 35% of FDA approved drugs target GPCRs (Foster & Conn, 2017; 
Hauser, 2018). 
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Classically, GPCRs were considered functional monomeric entities; this was based on 
evidence that purified monomeric family A GPCRs such as β2-adrenoreceptor, Rhodopsin, and 
the μ-opiate receptor reconstituted in a phospholipid bilayer, were sufficient for activation 
(Whorton, 2007; Whorton, 2008; Kuszak, 2009).  However, later evidence reported with regard 
to dopamine D2 receptors, that a minimal signaling unit of 2 receptors and one protein can cause 
activation, suggesting that class A receptors may homodimerize (Han et al., 2009). The 
asymmetrical interface of the D2 protomers seemed to modulate each other upon agonist and 
inverse agonist binding further supporting the case for GPCR dimerization. The topic of Class A 
GPCR dimerization is still debated today; however, other GPCRs such as class C metabotropic 
Glutamate (mGlu) and GABAB receptors have been reported to act as obligate dimers. For 
example, the mGlu family homodimers are linked covalently through disulfide bridges 
connecting their N-terminal Venus fly trap domain (Niswender, 2010.)  
Studies involving the GABAB (γ-aminobutyric acid type B) receptor also shed light on 
GPCR dimerization, specifically heterodimerization. GABA is the main inhibitory 
neurotransmitter acting though GABAB receptors; the original gene for the receptor, GABAB-R1 
was cloned in 1997 but the receptor was not expressed in cell lines. However, one year later, the 
GABAB-R2 subtype was shown to form a heteromeric complex with GABAB-R1 as shown in 
several studies (Jones, 1998, White, 1998; Kaupmann 1998.) Alone, neither protomer can both 
bind ligand and activate the G protein, but co-expression of both the GABAB-R1and GABAB-R2 
lead to a fully functional GABAB receptor (Jones, 1998, White, 1998; Kaupmann 1998).  
Dimerization involving GPCRs of distinct subtypes/families include the κ and δ opiate 
receptors in which the protomers have been shown to heteromerize and modulate each other 
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(Jordan, 1999). Another such heteromeric complex including distinct families of GPCRs and is 
of especial interest in schizophrenia is the mGlu2/5-HT2A heteromeric complex.  
The mGlu2/5-HT2A Heteromeric Receptor Complex  
As mentioned previously, psychedelics such as LSD can stimulate the 5-HT2A receptor 
resulting in psychosis like behavior, which can be behaviorally quantified in animal models. 
Recall that 5-HT antagonism is a mechanism of many second generational atypical antipsychotic 
drugs; thus, a GPCR containing 5-HT2A complexed with a glutamate receptor (glutamate is a 
main excitatory neurotransmitter in the brain) is of interest when considering therapeutic drugs 
for schizophrenia. Additionally, mGlu2/3 has been a target for some therapeutic agonists such as 
LY2140023 which have shown improvement in the positive and negative symptoms of 
schizophrenia (Patil, 2007) However, other mGlu2/3 agonists such as LY379268 require 5-HT2A 
expression inducing head twitch behavior in order to provide antipsychotic action in mice 
(Moreno, 2011; Hideshima, 2018). 
Although initial postmortem brain studies of schizophrenic patients reported mixed 
results regarding the density of serotonin receptors, a 2008 study using binding assays found that 
cortical membranes of untreated schizophrenic patients had increased densities of 5-HT2A 
receptors with concurrent decreases in mGlu2/3 levels.  This increase in 5-HT2A receptor density 
was not found in postpartum brains of patients treated with clozapine, which was attributed to 
chronic antipsychotic administration downregulating levels of 5-HT2A (Gonzalez-Maeso, 2008). 
Furthermore, the mouse studies found that “the mGluR2 component of the [mglu2/5-HT2A] 
complex eliminates the hallucinogen-specific component of the signaling in response to LSD-
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like drug; [thus this pattern of 5-HT2A and mGlu2 density may predispose schizophrenia.]” 
(Gonzalez-Maeso, 2008.) 
Functional cross talk has also been established between the two protomers of the 5-HT2A-
mGlu2 complex and is of relevance to schizophrenia. Recall the several pathways by which 
GPCRs can conduct a signal – the 5-HT2A receptor is Gq/11 coupled while the mGlu2 receptor is 
Gi/o-coupled. In general, the Gi/o coupled pathways inhibit the production of adenylyl cyclase 
while Gq/11 pathways lead to an increase in calcium release mediated by IP3/DAG. The existence 
of multiple signal transduction pathways in the heterodimer allows for assessment of the 
downstream interactions induced by either protomer. For example,  researchers found that when 
the 5-HT2A-mGlu2 complex was stimulated with LY379268, an mGlu2 agonist, there was also 
activation of Gq/11 proteins by the 5-HT2A portion of the complex; this did not occur in 5-HT2A 
deficient mice (Moreno, 2016).  
Further studies on the mGlu2/5-HT2A heteromeric complex, suggest that  
in response to endogenous ligands glutamate and serotonin, the mGlu2/5-HT2A heteromer 
establishes a Gi/o-Gq/11 balance which may result in behavioral responses different from 5-HT2A 
and mGlu2 homomers (Fribourg, 2011). In summary, the assembly of the heteromeric complex 
reduces 5-HT mediated Gq/11 signaling and increases mGlu2 mediated Gi/o signaling. There is a 
Gi/o-Gq/11 imbalance in psychosis that can be modulated by 5-HT2A and mGlu2 agonists or 
inverse agonists. For example, 5-HT agonists and mGlu2 antagonists shift the Gi/o-Gq/11 balance 
to those more similar to psychotic conditions than physiological conditions.  Likewise, mGlu2 
agonists and 5-HT inverse agonists would accelerate Gi/o signaling while diminishing Gq/11 
signaling – shifting the balance towards physiological conditions. See adopted schematic:  
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In a condition as complicated as schizophrenia, with several interconnected brain 
pathways being in balance with one another, there is a need for drugs that are multi-targeted. The 
transition from typical to atypical antipsychotic drugs shows the importance of considering 
additional protein targets involved in schizophrenia. The 5-HT2A-mGlu2 receptor complex is a 
prime example of such targets.  
Mutational Approaches to Map the Heteromeric Interface of 5-HT2A-mGlu2 
Several studies have taken a mutation-based approach to assess the hetero-dimeric 
interface of the mGlu2-5-HT2A complex. A study using immunocytochemistry verified the 
colocalization of 5-HT2A and mGlu2 in tissue. These studies shed light on the phenomena that 
mGlu2 but not mGlu3 colocalizes in cortical tissue and in cell culture (Gonzalez-Maeso, 2008.) 
A similar discrimination between 5-HT2A and 5-HT2C (in which only 5-HT2A but not 5-HT2C can 
dimerize with mGlu2) is used to assess the aims of my study. 
Schematic adopted from: Cell 147, 1011–1023, November 23, 2011 ª2011 Elsevier Inc. 
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 Specifically, previous studies have demonstrated the importance of TM4 in mGlu2 in 
mediating the heteromeric interface of the mGlu2-5-HT2A heterocomplex (Moreno, 2012). This 
study, in which residues of mGlu3 are swapped into mGlu2 at the predicted sites within the 
heteromeric interface, was assessed by coimmunoprecipitation to see if the interface could be 
broken. By this method, researchers were able to identify TM4 but not TM5 of mGlu2 as 
necessary for 5-HT2A-mGlu2 heteromerization (Moreno, 2012). Furthermore, the researchers 
created mutant mGlu3 chimeras with a TM4 domain from mGlu2 and found upon 
immunoprecipitation that TM4 of mGlu2 was also sufficient for mediating the heteromeric 
interface. (Moreno, 2012)  
A follow up study also implicated TM4 of 5-HT2A to be involved in mediating the 
heteromeric interface of the mGlu2-5-HT2A. This study first confirmed that WT 5-HT2A but not 
WT 5-HT2C coimmunoprecipitated with mGlu2 and could form a complex (Moreno, 2016.)  As 
mentioned earlier, this relationship between 5-HT2A and 5-HT2C is analogous to that of mGlu2 
and mGlu3. The mutant chimeras created in my thesis experiments included aligned residues 
from TM4 of 5-HT2C within portions of the TM4 of 5-HT2A in attempt to disrupt the binding 
interface of the heteromer. 
After Identifying TM4 of mGlu2 as the domain responsible for mediating 
heteromerization. Researchers identified Ala-6774.40, Ala-6814.44, and Ala-6854.48 as the 
individual amino acids responsible for the heteromeric interface in mGlu2 (Moreno 2012). The 
numbering system used to describe the residues above follows the Ballesteros-Weinstein 
numbering system for conserved GPCR residues (Ballesteros, 1995); in this system, the most 
conserved residue across species, R, within a given transmembrane domain, X, is denoted as 
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RX.50. All residues adjacent to RX.50 towards the N terminus are given sequentially decreasing 
numbers (RX.49, RX.48, etc,) while those towards the C terminus are given sequentially increasing 
numbers relative to RX.50). Since the Moreno, 2012 experiment was concerned with residues in 
TM4 of mGlu2, we see the corresponding Ballesteros-Weinstein numbering used. The findings 
of the paper were based on substitutions at these positions resulting in the abolishment of 
hallucinogenic behavior. A follow up study, with an emphasis on identifying a direct interaction 
between these residues and the heteromeric interface, utilized amber codon suppression to 
introduce photoreactive unnatural amino acid azF (p-azido-L-phenylalanine) at these sites along 
the intracellular end of TM4; they concluded that Ala-6774.40, Ala-6814.44, and Ala-6854.48 of 
mGlu2 are directly involved in mediating the heteromeric interface (Maeso Group, unpublished).  
 While this thesis is primarily focused on identifying halves of the transmembrane 
domain responsible for heteromerization rather than individual amino acids, the greater goal of 
this project is to eventually identify the individual residues of 5-HT2A responsible for mediating 
the heteromeric interface by following a similar approach taken with mGlu2. 
Coimmunoprecipitation studies can identify whether portions of 5-HT2A TM4 are involved in 
heteromerization but a coimmunoprecipitation assay cannot establish a direct interaction between 
amino acids. Several approaches, however, have described the use of photoreactive unnatural 
amino acids in GPCRs to cross link individual residues in close proximity with one another; such 
studies have been conducted in the CXCR4 GPCR implicated in HIV, and the neurokinin-1 
(NK1) family A GPCR (Grunbeck, 2011; Valentin-Hansen, 2014). The general method for this 
approach involves co-transfection of a “cocktail” of plasmids – a synthetase gene, a suppressor 
tRNA gene, and a gene encoding the GPCR to introduce an unnatural amino acid (UAA) at a site 
of interest, such as azF; when excited by ultraviolet light, azF can form chemical cross links with 
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a sensitivity of 3-5 angstroms; indicating the presence or lack of a direct interaction by the 
residues mutated (Huber, 2014). The mutant constructs created in this thesis, and the 
interpretation of their Co-IP results, can be used as a starting point in identifying individual 
amino acids by the photo-crosslinking methods described above, if found to be implicated in 
mediating the heteromeric interface of the mGlu2-5HT2A complex. 
 The dysregulation of several neurotransmitter systems in schizophrenia warrants closer 
consideration of the GPCRs involved in each pathway. The limitations of early antipsychotics 
focused primarily on dopamine receptors to alleviate the positive symptoms of schizophrenia 
were addressed by assessing the roles of other GPCRs such as 5-HT2A in the production of 
atypical antipsychotics. The benefit of such exploration demands consideration of additional 
proteins and protein complexes implicated in schizophrenia, such as the 5-HT2A-mGlu2. We 
consider a mutation-based approach to identify which portion of the 5-HT2A is involved in 
mediating the heteromeric complex.  
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Objectives 
Due to the biological relevance of GPCRS in neuropsychiatric disorders generally, and 
keeping in mind the changes in receptor density, particularly of the mGlu2 and 5-HT2A GPCRs 
in schizophrenia and their colocalization, this study aims to identify a portion of TM4 of the 5-
HT2A responsible for mediating the heteromeric interface within the mGlu2-5-HT2A complex. 
The implication of transmembrane domain four (TM4) within the 5-HT2A receptor in 
mediating heteromerization of the mGlu2-5-HT2A complex allows deeper investigation into the 
residues contained within it. It also begs a question: which half of the transmembrane domain 
may contain the residues responsible for the interface. With this in mind, my Masters research 
aims to identify whether the residues in the N terminal half of TM4 of 5-HT2A are involved in 
heteromeric complex formation. Because research has established that TM4 of 5-HT2A is 
necessary to form the mGlu2-5-HT2A complex (Moreno et al 2016), the study aims to ultimately 
identify residues within the TM4 of 5-HT2A that are necessary to form the mGlu2-5-HT2A 
complex. To do this, I substituted residues in half of the TM4 of 5-HT2A closest to the N 
terminus, with aligned residues in 5-HT2C to create 2 constructs. One of these constructs is 
considered partially mutated (5-HT2A-TM4ΔNP) while the other is considered a full mutation of 
half the TM4 residues lying closest to the N terminus (5-HT2A-TM4ΔNF). Essentially, the 5-
HT2A-TM4ΔNP (partial) chimera contains swapped 5-HT2C residues spanning a quarter length of 
the TM4 closest to the N terminus, while the 5-HT2A-TM4ΔNF (full) construct is mutated to 
include residues from 5-HT2C along the entire half of the TM4 of 5-HT2A closest to the N 
terminus.  All three constructs, (WT 5-HT2A, 5-HT2A-TM4ΔNP, 5-HT2A-TM4ΔNF) were 
transfected individually or co-transfected with mGlu2 and prepared into membranes before 
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running a co-immunoprecipitation experiment and subsequent western blot to test whether 
complex formation is disrupted. If the N terminal half of TM4 does indeed include residues 
responsible for mediating complex formation, we would expect a stronger Co-IP signal from the 
sample containing WT mGlu2 & 5-HT2A than compared to one containing co-transfection of 
mGlu2 & the Mutant 5-HT2A-TM4ΔNF or 5-HT2A-TM4ΔNP. Furthermore, we would expect the 
lack of a band (or at least a less intense band) in the coimmunoprecipitation of mGlu2 and any 
mutant chimera originally containing the residues responsible for mediating the heteromeric 
interface. This information would be extremely valuable in future studies pertaining to the 
greater goals of this project; the possibility of using photo-crosslinked unnatural amino acids 
would allow identification of individual 5HT2A residues directly interacting with the heteromeric 
interface of the mGlu2-5HT2A heteromeric complex. 
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Materials & Methods 
Wild Type Plasmid Preparation  
The constructs pcDNA3.1-c-Myc-5-HT2A-mCherry and pcDNA3.1-HA-mGluR2-
mCitrine, described previously in Moreno et al., 2016, were obtained. In brief, the WT 
metabotropic glutamate receptor was tagged N terminally with hemagglutinin (HA) and C-
terminally by mCitrine (a type of yellow florescent protein.) The WT serotonin receptor 5-HT2A, 
alternatively, is N-terminally tagged by c-Myc and C-terminally tagged with mCherry (a type of 
monomeric red florescent protein.) All mutant 5-HT receptor chimeras include the same tags 
described.  Tagging receptor constructs allows for use of antibodies specific to the tag – and thus 
the construct – during immunoblot and immunoprecipitation assays. Plasmids were purified and 
amplified by methods detailed below. 
Chimeric Human 5-HT2A Constructs with half of TM4 near N terminus Mutated with 
residues of 5-HT2C: partial (5-HT2A-TM4ΔNP) and full (5-HT2A-TM4ΔNF)  
In accordance with manufacturer instruction, QuickChange II site-directed mutagenesis 
kit (Stratagene) was used to modify the primary structure of the Human 5-HT2A receptor into full 
and partial chimeric constructs containing residues of 5-HT2C in the N terminal half of TM4. The 
protocol involves the designing of primers before adding them to template DNA and cycling 
temperatures to induce the mutations desired. For the partial mutant 5-HT2A-TM4ΔNP, the 
following forward and reverse primer were designed (duplex forming nucleotides highlighted): 
Forward: 5'-
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ATGGTCCAAACAGCAATGATTTTCATGATTGCCTTAGTTCTGGAGTTGAAGC-3'. 
Reverse: 5'-
GCTTCAACTCCAGAACTAAGGCAATCATGAAAATCATTGCTGTTTGGACCAT-3' 
The primers along with appropriate manufacturer included buffers and template c-myc-5-
HT2A- m-cherry (WT) construct DNA were Thermo-cycled with the following parameters: 1 
cycle at 95°C followed by 16 cycles of 30 minutes at 95°C, 1 minute at 55°C and 8 minutes at 
68°C. Following this, a restriction enzyme Dpn1 was used for 1 hour at 37°C to digest parent 
amplification products to yield the partial 5-HT2A-TM4ΔNP construct.  This chimera (TM4ΔNP) 
had the effect of substituting the consecutive Phenylalanine and Leucine found in WT 5-HT2A 
with the consecutive Isoleucine and Methionine found in WT 5-HT2C (Fig 3 & 4). 
For the construct (5-HT2A-TM4ΔNF) involving a complete mutation of the residues that 
lay in the half of TM4 closest to the N terminal of 5-HT2A, a similar approach to creating the 
partial chimera was used; however, the DNA template used before cycling was the 5TM4ΔNP 
partial construct described above. The forward and reverse primers designed for the mutation as 
follows (duplex forming nucleotides highlighted): 
Forward: 5'-
GATATACCTACTGATATGGTCCAAACAATAGCGATTTTCATGATTGCCTTAGTTCTG
GAG-3' 
Reverse: 5'-
TCCAGAACTAAGGCAATCATGAAAATCGCTATTGTTTGGACCATATCAGTAGGTATA
TC-3' 
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 The parameters for thermocycling were as follows: 1 cycle at 95°C followed by 18 
cycles of 30 minutes at 95°C, 1 minute at 55°C and 7 minutes at 68°C. Similar to the partial 
construct, Dpn1 restriction enzyme was used to digest the unmutated parent DNA. Ultimately 
this produced the full N terminal half TM4 chimera 5-HT2A-TM4ΔNF by substituting the 
consecutive Isoleucine and Alanine found in the 5-HT2A-TM4ΔNP (and in WT 5-HT2A) with the 
consecutive Alanine and Isoleucine found in 5-HT2C respectively. (Fig 3 & 4). 
Since all other residues located on the half of TM4 closest to the N terminal end of the 
GPCR are the same when considering the aligned sequence of 5-HT2A and 5-HT2C, the above 
two constructs are sufficient to assess the hypothesis of the paper. 
Purification, Amplification, and Sequencing of Constructs   
Wild Type constructs obtained were transformed into XL1-Blue super competent cells 
using the heat shock method and let to incubate overnight on Agar plates, before a single colony 
was picked.  This colony was let to grow on a shaker in LB broth at 37°C overnight before 
purification and amplification by the protocol described in QIAGEN Plasmid Maxi Prep. 
The products from the Site Directed Mutagenesis were transformed in a similar manner 
described above; however, the selected colony was first amplified using QIAGEN Plasmid Mini 
prep before being mixed with primer to be sent for sequencing. The primer used for sequencing 
of both Mutant constructs (5-HT2A-TM4ΔNP & 5-HT2A-TM4ΔNF) was as follows.: 5’-AGC 
TGA TAT GCT GCT GGG TT -3’. Following sequence verification, the constructs were 
retransformed and plated overnight, a colony to grow in broth was selected, and a Maxi Prep to 
amplify yield of the construct was conducted. 
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Maintenance of HEK 293 Cells 
Human Embryonic Kidney (HEK293) cells were used for transfection. These cells were 
incubated in a cell culture environment with 5% humidified CO2 at 37°C. The media selected to 
maintain the cells, Dulbecco’s modified Eagle’s medium (DMEM), includes pH sentsitive 
Phenol red and was further modified by the addition of dialyzed fetal bovine serum (dFBS) equal 
to 10% of the total volume of media and Penstrep equal to 1% of the total media volume (except 
immediately prior to transfection, as noted below). Cells were split routinely using fresh media in 
a ratio between 1:12 and 1:8, to allow for growth and for fresh media, and never passaged higher 
than 22 times. 
Transfection of HEK 293 cells 
 Plates containing HEK 293 cells prepared for transfection or co-transfection were 
aspirated of any media and replaced with DMEM containing only 10% dFBS but no Penstrep 
prior to transfection (although reducing the chances of contamination, Penstrep inhibits 
transfection.) Plasmid containing the desired construct was added to a vial of Gibco Opti-MEM 
media before Invitrogen Lipofectamine 2000 reagent was added according to manufactures 
instructions in a 1:2 protein to lipofectamine ratio in a separate vial of Gibco Opti-MEM media; 
the mixtures were allowed to incubate separately for 1 hour. Following incubation, the mixtures 
were combined and added to Penstrep free plates containing HEK 293 cells in DMEM (+10% 
dFBS). Cells were grown to 80% confluency before transfection. Media containing 
lipofectamine was removed 24 hours following transfection; cells were allowed a maximum of 
48 hours after transfection before harvesting as described below. 
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 Using the method described above, transfections of single plasmids were done using 6μg 
of DNA per plate (Ex:8 plates = 48μg of plasmids total) This corresponds to a lipofectamine 
ratio of 12μg per plate or 96μg total. This includes the individual transfection of the constructs  
HA-mGluR2-mCitrine, c-Myc-5-HT2A-mCherry, and c-Myc-5-HT2A-TM4ΔNP-mCherry.  
Considering co-transfection of the serotonin and glutamate GPCRs, the HA-mGluR2-
mCitrine plasmid and c-Myc-5-HT2A-mCherry plasmid were transfected in a ratio of 2:1 (For 
example, 6μg of mGlu2 and 3μg of 5-HT2A for a total of 9μg DNA per plate to be combined with 
18μg lipofectamine total). Co-transfection of the partial mutant c-Myc-5-HT2A-TM4ΔNP-
mCherry with HA-mGluR2-mCitrine was performed using the same ratio. The full mutant c-
Myc-5-HT2A-TM4ΔNF-mCherry is yet to be transfected. 
Preparation of Membrane from Cell Pellets 
 48 Hours following transfection, cells were harvested using calcium and magnesium free 
DPBS (Dulbecco’s Phosphate Buffer Saline;) the buffer allows cells to dissociate from the plate 
and be scraped into a falcon before centrifugation. The resulting cell pellets were frozen at  
-80°C before being prepared into membranes. 
  For such preparations, cell pellets were resuspended in Tris-HCL buffer and 
homogenized before centrifugation. Cell membrane isolation begins with Initial low speed 
centrifugation of the homogenized solution at 1,000 xg in 4°C, which pellets heavier cell 
organelles such as the nucleus. Centrifugation of the supernatant from the initial spin at high 
speed (40,000 xg) results in a cell membrane precipitate which can be washed with Tris-HCL 
and recentrifuged at the same speed. The resulting supernatant is thrown off leaving isolated cell 
membranes containing the GPCR plasmids of interest in the precipitate. 
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Co-Immunoprecipitation Studies 
 The initial co-immunoprecipitation was conducted using membrane preparations of co-
transfected wild type HA-mGluR2-mCitrine and c-Myc-5-HT2A-mCherry containing 1mg 
(1000μg) of protein. In this assay the prepared membrane samples were first exposed to RIPA 
lysis buffer and then solubilized to allow the GPCRs within the membrane to become surrounded 
by surfactant before being rotated with Protein A/G PLUS-Agarose immunoprecipitation beads. 
For wildtype assays, anti-c-myc antibody (Cell Signaling, catalog #2276) in a 1:100 
concentration was added to the beads mixture before overnight rotation at 4°C.,  Total Protein 
controls were taken prior to antibody addition and immediately after overnight rotation 
(supernatant from 14000RPM spin) before final solubilization of the immune complexes formed 
by the assay.  
 Products of the Co-IP (precipitate from 14000RPM spin after overnight rotation) were 
washed and resolubilized with buffer before being prepared for immunoblot analysis. An aliquot 
of the final wash step was also reserved for Western Blot analysis to detect Co-IP signal that may 
have been lost to the final wash steps. 
Protein Estimation and Western blotting 
In order to resolve equal amounts of protein in each lane during the SDS-PAGE process, 
the protein composition of membrane preparations was estimated using the Bradford Protocol. 
(Note that for co-transfected samples used in Co-IP experiments, protein composition was 
estimated prior to the Co-IP.) A spectrophotometer set to a wavelength of 595nm detects the 
blue-dye within reagent when bound to proteins. A standard curve was stablished by detecting 
the absorbance of increasing control amounts of Bovine Serum Albumin (BSA). The curve was 
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used to interpolate an estimated protein composition (in μg/μl) of the membrane preparations 
from cells transfected with WT c-myc-5-HT2A and c-myc-5-HT2A-TM4ΔNP receptors. 
Two immunoblot assays, one with the aim of analyzing the results of the Co-IP 
experiment (Figure 3) and another blot to verify expression of the partial chimera 5-HT2A-
TM4ΔNP (Figure 4) were conducted and shown in the Results & Discussion section.  
Western blot following Co-Immunoprecipitation: 
All samples were heated to 95 degrees at 5 minutes before loading onto a 12% polyacrylamide 
gel. Lanes 1 and 2 with Total Protein and Total Protein Analog (supernatant described above) 
respectively, were loaded with 20μl of sample and 5μl of Laemmli buffer each. Lane 3, 
composed of sample from a late wash step, and Lane 4 containing the final Co-IP products were 
loaded with the same specifications. The samples were let to resolve at 60V for 1 hour and then 
100V for 3 hours before overnight transfer to a nitrocellulose membrane in the cold room (30V). 
The membrane was blocked with buffer containing BSA, milk, and TBST to avoid nonspecific 
binding before adding antibody. The membrane was incubated in a 1:1000 dilution of primary 
antibody, HA-Rabbit Ab (Cell Signaling Catalog #2367), for 1 hour at room temperature. The 
membrane was then washed, blocked, and incubated in secondary antibody, Anti-Rabbit 
Horseradish peroxidase (HRP) conjugated Ab (Cell Signaling Catalog #7074) for 2 hours 
(1:5000 dilution) at room temperature before being visualized with enhanced chemiluminescence 
reagents (ThermoScientific) in accordance with manufacture instructions. 
Western Blotting to Verify Expression of the Partial Chimera 5-HT2A-TM4ΔNP 
All samples were heated to 95 degrees for 5 minutes before loading onto a 12% polyacrylamide 
gel. Both lanes of the gel were loaded with a volume equal to 20μg of protein by mixing the 
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appropriate volume with 5μl of 5x Laemmli buffer and Tris-HCL up to a total sample volume of 
25μl per lane. SDS-PAGE was conducted at 60V for 1 hour and 100V for 2.5 hours before being 
transferred onto a nitrocellulose membrane overnight at 30V in 4°C. Following wash and 
blocking steps, the membrane was incubated in primary antibody, c-Myc-Tag-Mouse Ab (Cell 
Signaling, catalog #2276) for 1 hour (1:000 dilution) before being washed, blocked, and 
incubated in Anti-Mouse Horseradish peroxidase (HRP) conjugated secondary Ab (Cell 
Signaling, catalog  #7076) in a 1:5000 dilution. Visualization of the immunoblot of the chimeric 
construct was conducted using the same chemiluminescence reagents mentioned earlier. 
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Results and Discussion 
 Prior studies suggested that TM4 of 5-HT2A is necessary for mediating heteromerization, 
with this in mind, my study developed two mutant constructs 5-HT2A-ΔTM4NP and 5-HT2A-
ΔTM4NF, consisting of residues from 5-HT2C swapped into sections of the TM4 domain. 
Although the chimeras are named “partial” and “full”, it is important to consider that they only 
consider one half, (the N terminal half,) of TM4 with regards to nomenclature. The sequencing 
results of both constructs are displayed in Figures 1 (next page) and suggest that the desired 
mutations were made in the correct positions. Figure 1 highlights which portions of TM4 are 
considered the N terminal half as opposed to the C terminal half.  
 The choice to design chimeric constructs mutated on the N terminal half of TM4 rather 
than on the C terminal half was simply a matter of convenience. Figure 1 and 2 (displayed on 
horizontal pages blow) clearly show the mutation of 2 sequential amino acids (FLIM) 
followed by the mutation of 2 other sequential amino acids (IAAI); because the mutated 
residues were sequential, they could each be created using a single site directed mutagenesis 
protocol. Figure 2 also highlights the individual nucleotides which needed to be swapped for the 
mutation to occur – notice in the orange box for example showing the partial chimeric construct 
(FLIM) only three out of the six nucleotides required to form the two residues needed to be 
swapped, while in the full TM4 chimera (IAAI) four out of 6 nucleotides needed to be 
changed. To simplify the process of making mutations, I chose to begin with the N terminal half 
of TM4. However, additional C terminal chimeras may need to be made in future studies, using 
the same strategies shown in figures 1 and 2, if the full N terminal half TM4 chimera (5-HT2A-
ΔTM4NF) fails to break immunoprecipitation of the 5-HT2A-mGlu2 complex.  
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Figure 1. Alignment of residues in Human 5-HT2A and 5-HT2C along with both partial (5-HT2A-TM4ΔNP) and full (5-HT2A-TM4ΔNF) 
TM4 N terminal half mutants. The entire TM4 of 5-HT2A receptor is outlined in black. The N terminal half of the Transmembrane 
domain is highlighted as the left box within the TM4 outline corresponding to A2064.42 through W2144.50. Sequence consensus of all 
four constructs is displayed.  The 5-HT2A-TM4ΔNP construct replaces the phenylalanine4.43 and leucine4.44 found in 5-HT2A with the 
consecutive isoleucine4.44 and methionine4.55 found in WT 5-HT2C. The 5-HT2A-TM4ΔNF construct incudes the same residue changes 
as 5-HT2A-TM4ΔNP with the following additions: the consecutive isoleucine4.47 and alanine4.48 found in 5-HT2A are substituted with 
the consecutive alanine4.47 and isoleucine4.48 found in 5-HT2C. Notice that all other residues denoted as within the TM4 N terminal half 
of 5-HT2A share homology with the 5-HT2C receptor so have not been mutated. 
TM4 N terminal Half 
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Figure 2. Nucleotide Sequence alignment of Human 5-HT2A and 5-HT2C and both partial (5-HT2A-TM4ΔNP) and full (5-HT2A-
TM4ΔNF) TM4 N terminal half mutants.  The black box denotes the half of TM4 closest to the N terminal of the GPCR. In the partial 
(5-HT2A-TM4ΔNP) chimera, the TTT coding for Phenylalanine4.43 and CTG coding for Leucine4.44 from 5-HT2A were replaced with 
ATC (Isoleucine4.43) and ATG (Methionine4.44) naturally found in 5-HT2C as shown in the orange box. The blue box highlights changes 
made to produce the full (5-HT2A-TM4ΔNF) chimeric construct in addition to the residues mutated in 5-HT2A-TM4ΔNP: the ATT and 
GCT coding for Isoleucine4.47 and Alanine4.48 respectively were substituted with GCT and ATT, matching the sequence of 5-HT2C. 
Notice that some nucleotides in the figure appear to differ in mutant constructs than in 5-HT2C; it is important to note however that 
multiple codons can code for the same amino acids (ex: GCA and GCC both code for Alanine while ATC and ATT both code for 
Isoleucine. Thus, certain individual nitrogenous bases need not be mutated to achieve the sequence of residues desired for each 
construct
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The coimmunoprecipitation experiment in this study was assessed by Western Blot 
shown in Figure 3 and confirms results obtained in (Moreno 2012) suggesting that WT 5-HT2A 
and mGlu2 immunoprecipitated when co-transfected in HEK293 cells. 
Figure 3. Western blot probing for HA (tagged as HA-mglu2) following Coimmunoprecipitation 
involving a c-Myc Antibody (tagged as c-Myc-5-HT2A). Aliquots of sample before Co-IP antibody 
was added (lane 1) and samples of supernatant after overnight Co-IP rotation but before final 
wash or solubilization buffers were added (lane 2). Lane 1 and 2 are used as Total Protein 
references. Lane 4 corresponds to sample yielded after completing the entire Co-IP protocol, 
while Lane 3 includes sample from a late wash step which some Co-IP signal may have been lost 
to. All four lanes probed for HA-mGlu2 with Primary Antibody: HA-Tag Rabbit Ab; Secondary 
Antibody: Anti-Rabbit HRP Ab. 
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Figure 3 shows that the Co-IP lane (lane 4) has 2 clear molecular weight bands at near 
120 kDa and near 240 kDa which correspond to WT HA-mGluR2-mCitrine in its monomeric 
and dimeric forms respectively (Maeso Group, unpublished). The wash step sample in lane 3 
contains identical bands to those in lane 4; this is not surprising as the wash step sample was only 
included to detect any Co-IP signal lost to the final wash steps in the protocol. Lane 1 and 2 are 
total protein control lanes, meaning that signal in the Co-IP lane should not be present unless 
also present in the Total Protein lanes 1 and 2; our results are congruent with this idea. Bands 
displayed below 100 in the total protein lanes may be attributed to nonspecific binding which 
was lost in the Co-IP and wash lanes after final solubilization steps. 
To assess the hypothesis of the paper, the full chimeric construct (5-HT2A-ΔTM4NF) 
should first be coimmunoprecipitated with WT mGlu2. We can either expect the presence of a 
Co-IP band or absence of a Co-IP band 
If 5-HT2A-ΔTM4NF CAN coimmunoprecipitate with mGlu2 (band present) 
 There are multiple reasons for a result in which 5-HT2A-ΔTM4NF and mGlu2 can 
coimmunoprecipitate and display a band. It may be that N terminal half TM4 residues do not 
mediate the heteromeric interface of 5-HT2A-mGlu2 complex. Or they may still show Co-IP 
signal, but one that is weak in comparison to that of a full C terminal chimera which does not 
disrupt coimmunoprecipitation at all. The best way to assess this result would be to create a 5-
HT2A chimera considering the full C terminus half of TM4 (for example: 5-HT2A-ΔTM4CF) and 
compare the coimmunoprecipitation results from both constructs. If the 5-HT2A-ΔTM4NF 
produces a band while the 5-HT2A-ΔTM4CF does not, then the residues responsible for 
mediating heteromerization are located in the C terminal half of the TM4 in 5-HT2A. However, if 
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both constructs display a Co-IP signal, a quantification of the Co-IP signal is necessary. A 
method similar to Moreno, 2012 in which coimmunoprecipitation of both N terminal and C 
terminal half TM4 chimeric constructs of mGlu2 containing residues from mGlu3 both produced 
Co-IP signal, can be followed: after running multiple experiments, the signals were aggregated 
and quantified in terms of immunoreactivity. The same approach can be used with multiple 
chimeras producing Co-IP signal. The chimera with the lowest immunoreactivity is likely to be 
responsible for mediating the heteromeric interface of 5-HT2A. 
If 5-HT2A-ΔTM4NF can NOT coimmunoprecipitate (band absent): 
 This would validate the hypothesis of the experiment. A lack of Co-IP signal would 
indicate that the heteromeric interface was broken when the N terminal half was mutated – 
suggesting that one or more of original residues (phenylalanine4.43; leucine4.44; alanine4.47; 
isoleucine4.48) in the N terminal half of TM4 in 5-HT2A mediate complex formation. Co-IP of the 
partial mutant could be used to assess which set of residues FL or IA is more responsible; 
however, a Co-IP experiment does not differentiate direct interaction of proteins from indirect 
interaction via additional scaffolding proteins. Additional approaches such as crosslinking 
photoreactive unnatural amino acids to identify the individual residues responsible, as described 
further in the future directions section can be used,  
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Figure 4. Characterization of Partial TM4 Mutation with Western Blot probing for c-myc-5-
HT2A; Ladder merged for Clarity. Lane one samples were previously transfected with WT 5-HT2A 
receptor. Lane two was loaded with sample previously transfected with the partial mutant (5-
HT2A-ΔTM4NP). Primary Antibody: Myc-Mouse Ab. Secondary Antibody: Anti-Mouse Ab. 
Finally, figure 4 attempts to characterize the mutant receptor by immunoblot assay. If the 
mutant is expressed properly, we would expect bands of similar molecular weight for both 
mutant and wild type receptors. While the immunoblots do not indicate a 53kDa band expected 
by a monomeric 5-HT2A receptor, one must account for the weight of c-myc (41kDa) and m-
cherry tags on 5-HT2A (29kDa) in addition to the possibility of the receptor dimerizing or 
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oligomerizing. In any case, since the mutant plasmids must be translated by the cell without 
misfolding or being degraded, the homology of the bands indicated on the western blot suggest 
that the 5-HT2A-ΔTM4NP chimeric receptor was properly expressed in a manner similar to WT 
5-HT2A. The purpose of selecting the partial chimera 5-HT2A-ΔTM4NP in Figure 4 was to ensure 
that the partial chimera displayed molecular weight bands similar to that of wild type receptors, 
before creating the full N terminal TM4 chimera 5-HT2A-ΔTM4NF. The full construct and any 
additional C terminal 5-HT2A chimeras can also be characterized by immunoblot.  
 There are several additional ways to characterize the mutant receptors in future studies 
and ensure structural and functional similarity to wild type receptors. To assess whether the 
mutant receptors bind to ligands in a manner similar to WT 5-HT2A, radioactive Ketanserin 
binding experiments as outlined in Moreno, 2016 could be conducted. We would expect similar 
displacement curves for individually transfected mutant and wild type receptors. The binding 
between curves of co-transfected wild type receptors and co-transfected mutant 5-HT2A chimeras 
with mGlu2 should slightly vary depending on the mutation in the chimera. Additionally, 
experiments considering the cross talk between the protomers of the complex, using LY379268, 
(an mGlu2 agonist) as described in (Moreno 2016) could be conducted. We would only expect 
downstream 5-HT2A Gq/11 calcium signaling in mutant chimeras which are not responsible for 
breaking the binding interface. Finally, to assess the proper localization of the protein following 
translation, Immunocytochemistry experiments as those described in Gonzalez-Maeso, 2008 can 
be conducted. We would expect a distribution of mutant receptors similar to that of wild type 
receptors. Mutant receptors could also be co-transfected with mGlu2 before comparing their 
immunocytochemistry results to those of WT co-transfection. 
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Conclusions and Future Directions 
Findings: 
1. Immunoblot experiments conducted in this study are congruent with previous findings 
that wild type mGlu2 and 5-HT2A coimmunoprecipitate 
2. Mutant constructs (5-HT2A-ΔTM4NP and 5-HT2A-ΔTM4NF) created in this study can 
assess the hypothesis of the paper using the same methods for Co-IP. 
a. Multiple Co-IP signals can be discriminated by quantification 
b. Additional chimeric constructs involving the C terminal half of 5-HT2A/C can be 
made (ex: 5-HT2A-ΔTM4C-P/F) to assess their role in heteromerization. 
3. Expression of the partial mutant is verified by similar immunoblot bands displayed for 
WT 5-HT2A and 5-HT2A-ΔTM4NP western blot.  
4. Additional characterization of any constructs produced by this study or those created in 
the future may include: 
a. Immunocytochemistry 
b. [H3] Ketanserin Binding 
c. Crosstalk experiments (Calcium Assay) 
Future Directions if the 5-HT2A N terminal half of TM4 is determined to mediate the 
heteromeric interface: Photo-Crosslinking Approach 
If no co-immunoprecipitation between 5-HT2A-ΔTM4NF and mGlu2 is observed, a photo-
crosslinking approach similar to Grunbeck, 2011 & Valentin-Hansen, 2014, mentioned earlier, 
could be used to identify individual amino acids involved in the interface. Recall that while 
coimmunoprecipitation offers valuable information on the sections of the TM4 involved in 
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heteromerization, it does not offer evidence for a direct interaction between individual amino 
acids. Although traditional cysteine cross linking experiments such as ones used to identify a 
homomeric dopamine receptor (Han. 2009) can be used to assess a direct interaction, the 
presence of endogenous cystines mediating the Venus Fly Trap domains of mGlu2 presents a 
problem; although these cystines can be mutated to serine or alanine, this substitution seems to 
alter the structure and dynamics of the mGlu2 homodimer (Koehl, 2019.) While the technical co-
transfection of multiple plasmids required by a photo-crosslinking approach may take additional 
optimization, the approach taken by Maeso Group, Unpublished to identify individual amino 
acids responsible in the mGlu2 receptor, could be modeled to identify the individual residues of 
5-HT2A responsible for complex formation without compromising the overall structural integrity 
of either protomer in the complex. 
If the N terminal end residues of TM4 in the 5-HT2A are found to be implicated in the 
dimeric interface, that is, if coimmunoprecipitation of the mGlu2 and 5-HT2A-ΔTM4NF fails to 
occur, four separate constructs would need to be created to perform a photo cross linking assay. 
The four new constructs correspond to the four residues mutated (phenylalanine4.43; leucine4.44; 
alanine4.47; isoleucine4.48) to create the 5-HT2A-ΔTM4NF construct. The “cocktail” of plasmids 
transfected, would be refined to introduce a single photoreactive unnatural amino acid 
corresponding to phenylalanine4.43, leucine4.44, alanine4.47, or isoleucine4.48 in each of the four new 
constructs respectively. These constructs could undergo UV mediated crosslinking, which would 
reveal whether one or more of the four original amino acids mutated in 5-HT2A form a direct 
interaction with mGlu2 and participate directly in establishing the heteromeric interface of the  
5-HT2A-mGlu2 complex. 
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The implication of the mGlu2-5-HT2A complex in schizophrenia is clear. The results 
produced in this study offer valuable constructs to be included in designing future studies. With 
the mutant constructs created, Co-IP assays can be conducted with the same methods to identify 
if either disrupts the binding of 5-HT2A-mGlu2. If so, future photo-crosslinking studies can focus 
on identifying individual amino acids within 5HT2A responsible for the heteromeric interface. If 
not, additional C terminal TM4 chimeras of the 5-HT2A with aligned residues from 5-HT2C will 
need to be constructed, coprecipitated, and immunoassayed before verifying the role of the C 
terminal residues. In any case, gaining a more complete structural understanding of the mGlu2-5-
HT2A will be beneficial for therapeutic strategies in Schizophrenia.
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